|
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors Clinical research trials and Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors. Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors clinical trial. Test subjects typically obtain the finest healthcare available for their Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors  Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific,Quality of Life,Cachexia
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Norris Cotton Cancer Center
Synopsis: RATIONALE: Adenosine triphosphate may decrease weight loss and improve muscle strength in patients with advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of adenosine triphosphate in controlling loss of weight and loss of muscle mass in patients who have advanced solid tumors.
Details: OBJECTIVES: I. Determine the individualized maximum tolerated dose of adenosine triphosphate in patients with advanced solid tumors. II. Determine the safety of this regimen in these patients. III. Determine the pharmacokinetics of this regimen in these patients. IV. Determine the effect of this regimen on quality of life of these patients. V. Determine the influence of this regimen on cancer cachexia in terms of weight change, percentage of body fat, voluntary muscle strength, and plasma markers in these patients. VI. Determine the effect of this regimen on tumor burden in these patients. PROTOCOL OUTLINE: This is a dose-escalation study. Patients receive adenosine triphosphate (ATP) IV over 8 hours on day 0. Treatment repeats weekly for a total of 8 courses in the absence of disease progression or unacceptable toxicity. Each patient receives escalating doses of ATP until the individual maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which the patient experiences at least grade 3 (at least grade 2 cardiac ischemia or arrhythmia) toxicity. Weight is measured at baseline and at weeks 1-8, 10, and 13. Percentage of body fat and skeletal muscle strength is measured at baseline and at weeks 2, 4, 8, 10, and 13. Quality of life is assessed at baseline and at weeks 2, 4, 8, 10, and 13. Patients are followed at weeks 10 and 13. PROJECTED ACCRUAL: A maximum of 13-24 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically or cytologically confirmed advanced solid tumor that is not curable by conventional therapy - Brain metastases allowed if adequately controlled with radiotherapy --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy: Not specified Radiotherapy: - See Disease Characteristics - At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified Other: - At least 30 days since prior investigational therapy - At least 14 days since prior long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy - No concurrent long-term theophylline, dipyridamole, or dipyridamole/aspirin therapy - No concurrent maintenance anti-anginal drug therapy --Patient Characteristics-- Age: Over 18 Performance status: Karnofsky 60-100% Life expectancy: At least 12 weeks Hematopoietic: - WBC at least 3,500/mm3 - Absolute neutrophil count at least 2,000/mm3 - Platelet count at least 100,000/mm3 Hepatic: - SGOT and SGPT no greater than 3 times normal - Bilirubin no greater than 2.0 mg/dL Renal: - Creatinine no greater than 1.5 mg/dL - Creatinine clearance greater than 60 mL/min - BUN no greater than 25 mg/dL Cardiovascular: - Adequate cardiovascular function - No congestive heart failure (New York Heart Association class III or IV heart disease) - No angina pectoris AND/OR - No significant arrhythmia - No myocardial infarction within the past 6 months - No clinically significant ischemic cardiac disease currently under treatment - No clinically significant conduction system disease in the absence of a pacemaker (e.g., sick sinus syndrome, or second or third degree atrioventricular block) Pulmonary: - Adequate pulmonary function - No clinical evidence of acute chronic obstructive pulmonary disease - FEV1 at least 50% predicted - Arterial oxygen tension at least 90% by pulse oximetry and on breathing room air - No asthma OR - No evidence of more than 20% reversibility in FEV1 with albuterol therapy Other: - Not pregnant or nursing - Fertile patients must use effective contraception - No history of severe adverse reaction to adenosine - No uncontrolled medical illness - No average daily pain scores of at least 5 on a simple Visual Analogue Self pain assessment (0-10) scale
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LionelLewis, Study Chair, Norris Cotton Cancer Center
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
United States
Additional Information:
Study ID Numbers: CDR0000068522; NCI-G01-1923,ATP-DMS-0005,DMS-0005
Study Start Date: October 2000
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00014248
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
2. Stress Management Training in Patients Undergoing Radiation Therapy for Cancer
3. Quality-of-Life Assessment in Patients With Ovarian Cancer
4. Epoetin alfa With or Without Filgrastim Compared With Blood Transfusions in Treating Patients With Myelodysplastic Syndrome
5. Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other New Hampshire Clinical Trials
Other Lebanon Clinical Trials
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
